ICMRA Review Finds Remote Alternatives Could Complement Onsite Inspections, Not Replace Them
Executive Summary
Stance echoes US FDA’s view that remote alternatives should be “supplemental tools” to support in-person inspections.
You may also be interested in...
How The US FDA’s Inspectional Approach Is Shifting For The Post-Pandemic Era
Agency hints of a “hybrid” future of in-person inspections supplemented by alternative tools like remote interactive evaluations.
World’s Pharmaceutical Inspectorates Prepare For Post-Pandemic Remote Site Assessments
US, EU, global authorities share experiences, insights, advice for industry on remote alternatives even after inspectors can resume travels.
Remote Site Visits Will Help US FDA Keep Reviews On Track During Remainder Of Pandemic
Video facility tours expected to help clear way for timely drug and biologic approvals while COVID-19 still prevents inspections.